Health-Holland

Highly regarded for its excellent scientific knowledge, involved physicians and scientists, and the cooperation of patients, the Netherlands plays a significant role in the conducting of clinical drug trials. The country’s dense network of research institutes and general practitioners also helps to ensure a high level of patient registration. Facts and figures Every year, approximately 500 new clinical trials are submitted to the CCMO (The Central Committee on Research Involving Human Subjects) for approval, of which approximately 97% are approved. In 2017, the CCMO and the medical ethics committees evaluated a total of 1657 research files, of which 548 (33%) were clinical drug trials. The majority of the clinical drug trials were submitted by industry (61%) and were Phase 3 studies (30%). In 2018, data from the web-based resource ClinicalTrials.gov showed that there were 773 active clinical trial studies in the Netherlands and 1486 studies that were recruiting participants. These numbers are on a par with neighbouring country Belgium. The Netherlands performs a relatively high number of clinical trials per capita in comparison with France, Germany and United Kingdom. Clinical research Source: Annual report CCMO 2017 Source: Annual report CCMO 2017 Source: Annual report CCMO 2017 Source: Annual report CCMO 2017 Research files (2017) Clinical drug trials per phase (2017) Clinical drug trials by industry and non-industry (2017) Participants (2017) Observational research 639 = 39% Other intervention research 470 = 28% Research with medicines 548 = 33% Phase I 123 = 22% Research with medicines 41,125 = 18% Phase II 147 = 27% Other intervention research 62,263 = 27% Observational research 127,903 = 55% Phase III 163 = 30% Fase IV 62 = 11% Other 44 = 8% N/A 9 = 2% Industry 333 = 61% Non-Industry 215 = 39% 1,657 231,291 25